RomidepsinOther Names: FK228, Istodax, RMD Drug Class: Latency-Reversing Agents Molecular Formula: C24 H36 N4 O6 S2 Registry Number: 128517-07-7 (CAS) Chemical Name: (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone Chemical Class: Cyclic tetrapeptide Organization: Celgene Corporation Phase of Development: Romidepsin is in Phase II development as a latency-reversing agent for HIV treatment.
(Compound details obtained from ChemIDplus Advanced,1 Treatment Action Group website,2 Celgene Corporation website,3 Journal of Biomedicine and Biotechnology article,4 and EudraCT 2015-003186-28 clinical trial protocol5)
What is an investigational drug?
Anis one that is under study and is not approved by the U.S. (FDA) for sale in the United States. Medical research studies are conducted to evaluate the safety and effectiveness of an investigational drug. These research studies are also called clinical trials. Once an investigational drug has been proven safe and effective in clinical trials, FDA may approve the drug for sale in the United States.
To learn more about investigational drugs, read the What is an Investigational HIV Drug? fact sheet.
What is romidepsin?
Romidepsin (brand name: Istodax) is a FDA-for the treatment of certain types of cancer. Romidepsin is currently being studied to see if it could be effective as part of a strategy to cure HIV .5-10
Currently, there is no cure for HIV infection. One of the main obstacles to curing HIV infection is that thecan remain hidden and inactive (latent) inside certain cells of the (such as resting CD4 T cells) for many months or even years. While HIV is in this latent state, the immune system cannot recognize the virus, and (ART) has no effect on it. (ART is the recommended treatment for HIV infection and involves using a combination of different [ARV] drugs to prevent HIV from replicating.)11,12
Romidepsin belongs to a general class (group) of HIV drugs called latency-reversing agents.2 There are different types of latency-reversing agents. Romidepsin is a type of latency-reversing agent called a histone deacetylase (HDAC) inhibitor.13
How do latency-reversing agents work?
Latency-reversing agents reactivate (turn back on) latent HIV within resting CD4 T cells. When latent HIV is reactivated, it is once again able to produce new virus and multiply (). It is hoped that after latent HIV is reactivated, the CD4 T cells in which the virus was hiding are more likely to die off on their own or be recognized and killed by the body’s immune system.12,13
In addition, any new virus that is produced during reactivation can then be prevented from infecting other cells with the use of ongoing ART.12,13 Recent research has shown that additional therapies, together with latency-reversing agents, may be needed to fully eliminate latent HIV from the body.13
How are clinical trials of investigational drugs conducted?
Clinical trials are conducted in phases. Each phase has a different purpose and helps researchers answer different questions.14
- Phase I trials: Researchers test an investigational drug in a small group of people (20–80) for the first time. The purpose is to evaluate its safety and identify side effects.
- Phase II trials: The investigational drug is administered to a larger group of people (100–300) to determine its effectiveness and to further evaluate its safety.
- Phase III trials: The investigational drug is administered to large groups of people (1,000–3,000) to confirm its effectiveness, monitor side effects, compare it with standard or equivalent treatments, and collect information that will allow the investigational drug to be used safely.14
In most cases, an investigational drug must be proven effective and must show continued safety in a Phase IIIto be considered for approval by FDA for sale in the United States. Some drugs go through FDA’s accelerated approval process and are approved before a Phase III clinical trial is complete. After a drug is approved by FDA and made available to the public, researchers track its safety in Phase IV trials to seek more information about the drug’s risks, benefits, and optimal use.14
Some clinical trials are categorized as “a” or “b,” such as “Phase Ia” or “Phase IIb.” These different subphases typically mean that a study is researching certain types of information or using a certain type of participant population.
In what phase of testing is romidepsin?
Romidepsin is being studied in Phase II clinical trials.5,10
What are some studies on romidepsin?
Study Names: REDUC; NCT02092116
Sponsor: Bionor Immuno AS
Status: This study has been completed.
- Participants were adults with HIV who were on ART at the start of the study and who had been on ART for at least 1 year.
- Participants had levels (the amount of HIV in a blood sample) of less than 50 copies/mL for at least 1 year.
- Participants had CD4 counts of at least 500 cells/mm3, and their lowest ever CD4 counts in the past 2 years were no less than 200 cells/mm3. (A is a laboratory test that measures the number of CD4 cells—a type of immune cell—in a sample of blood and is an important indicator of immune function.)
Purpose: The REDUC trial was a 2-part study. Part A was designed to find a safe and effective Vacc-4x when combined with romidepsin, and (2) whether this drug combination could reduce the amount of latent HIV in the body and control viral load levels during a planned break from ART.7,15of romidepsin to use in the second part of the study. Part B was designed to evaluate (1) the safety of the investigational therapeutic
Study Names: ACTG 5315; NCT01933594
Status: This study is ongoing, but not recruiting participants.
Location: United States
- Participants are adults with HIV who have been on an ART regimen containing 2 or more efavirenz (brand name: Sustiva), raltegravir (brand name: Isentress), or dolutegravir (brand name: Tivicay) for at least 90 days before starting the study. inhibitors (NRTIs) plus
- Participants have had viral load levels of less than 50 copies/mL for at least 1 year before starting the study.
- Participants have had CD4 counts of at least 300 cells/mm3 within a 1- to 3-month period before starting the study.
Purpose: The purpose of this study is to look at the safety of single and multiple doses of romidepsin and to determine the effectiveness of single and multiple romidepsin doses in reactivating latent HIV within resting CD4 T cells.8
Study Identifiers: ROADMAP; NCT02850016
Sponsor: Rockefeller University
Status: This study is currently recruiting participants.
Locations: Denmark, Germany, United States
- Participants are adults with HIV who have been receiving ART for at least 24 months.
- Participants who are on an ART regimen containing a cobicistat must be willing to switch to an ART regimen that contains an inhibitor before starting the study. , a , or the drug
- Participants have had viral load levels of less than 50 copies/mL for at least 18 months and have CD4 counts greater than 500 cells/mm3 at the start of the study.
Purpose: The purpose of this study is to compare the effectiveness of romidepsin plus the investigational 3BNC117 to the effectiveness of romidepsin administered alone in controlling viral load during a treatment interruption. (A treatment interruption is a planned break from HIV medicines to evaluate how well an investigational drug can maintain control of a participant’s viral load during a clinical trial.)10drug
Study Names: BIOSKILL; EudraCT 2015-003186-28
Sponsor: Bionor Pharma ASA
Status: This study is ongoing.
Locations: Australia, Europe, United States
- Participants are adults with HIV who have been receiving ART continuously for at least 3 years.
- Participants have maintained viral load levels of less than 20 copies/mL and have CD4 counts of 500 cells/mm3 or more at the start of the study.
- Participants’ lowest ever CD4 counts were 250 cells/mm3 or above.
Purpose: The purpose of this study is to evaluate the safety and effectiveness of the combined use of Vacc-4x and romidepsin. The researchers will measure the effects of Vacc-4x and romidepsin on viral load, latent HIV, and the body’s immune responses.5
Study Names: eCLEAR; NCT03041012
Sponsor: Aarhus University Hospital
Status: This study is currently recruiting participants.
- Participants are adults with HIV who have never taken ART.
- Participants have CD4 counts of more than 200 cells/mm3 at the start of the study.
Purpose: The purpose of this study is to evaluate the effect of romidepsin, 3BNC117, or both on size when given soon after ART is started in adults who have never previously taken ART.16
For more details on the studies listed above, see the Health Professional version.
Another study, the BCN02-Romi trial (NCT02616874), is a Phase I trial that is looking at the use of an investigational therapeutic vaccine called MVA.HIVconsv in combination with romidepsin in participants who have already received investigational therapeutic vaccines during a separate trial.9,17
What side effects might romidepsin cause?
One goal of HIV research is to identify new drugs that have fewer side effects. The following side effects were observed in some of the studies of romidepsin listed above.
In Part A of the REDUC trial, all romidepsin-related side effects were mild in severity and resolved within a few days. The most common side effects related to romidepsin were abdominal symptoms (such as nausea, stomach growling, and abdominal pain) and fatigue. Some mild changes incounts and T cell counts were seen.15
In Part B of the REDUC trial, the majority of side effects were mild in severity. Side effects associated with romidepsin included fatigue and nausea. One side effect associated with romidepsin—mild hair loss—did not resolve by the end of the study. Side effects related to Vacc-4x plus the and to the treatment interruption also occurred.18
ACTG 5315 (NCT01933594):
Participants receiving romidepsin tolerated the drug well and had no treatment-related serious side effects.8,19
For more information on known side effects of romidepsin, see the Full Prescribing Information for the approved use of romidepsin to treat certain types of cancer.
Because romidepsin is still being studied, information on possible side effects of the drug is not complete. As testing of romidepsin continues, additional information on possible side effects will be gathered.
Where can I get more information about clinical trials studying romidepsin?
More information about romidepsin-related research studies is available from the AIDSinfo database of study summaries. Click on the title of any trial in the list to see the ClinicalTrials.gov trial summary and more information about the study.
How can I find more information about participating in a clinical trial?
Participating in a clinical trial can provide benefits. For example, a volunteer participant can benefit from new research treatments before they are widely available. Participants also receive regular and careful medical attention from a research team that includes doctors and other health professionals. However, clinical trials may also involve risks of varying degrees, such as unpleasant, serious, or even life-threatening side effects from the treatment being studied.14
Your health care provider can help you decide whether participating in a clinical trial is right for you. For more information, visit NIH Clinical Research Trials and You.
- United States National Library of Medicine. ChemIDplus Advanced. Available at: https://chem.nlm.nih.gov/chemidplus/rn/128517-07-7. Last accessed on April 10, 2018.
- Treatment Action Group website. Research toward a cure trials. Available at: http://www.treatmentactiongroup.org/cure/trials. Last accessed on April 10, 2018. [Archived at WebCite]
- Celgene Corporation website. Therapies. Available at: https://www.celgene.com/therapies/. Last accessed on April 10, 2018. [Archived at WebCite]
- Masetti R, Serravalle S, Biagi C, and Pession A. The role of HDACs inhibitors in childhood and adolescence acute leukemias. J Biomed Biotechnol. Vol 2011; Article ID 148046. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3026992/pdf/JBB2011-148046.pdf. Last accessed on April 10, 2018.
- EU Clinical Trials Register. EudraCT Number: 2015-003186-28; BIOSKILL: studying Vacc-4x, an HIV therapeutic vaccine, an assessment of immune-mediated anti-viral effects, when administered with adjuvant GM-CSF prior to HIV latent reservoir activation by the HDAC inhibitor, romidepsin. Available at: https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-003186-28/DK. Last accessed on April 10, 2018. [Archived at WebCite]
- Celgene Corporation. ISTODAX – romidepsin: full prescribing information, October 2014. DailyMed. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03b39d40-90fe-11df-9de6-0002a5d5c51b. Last accessed on April 10, 2018. [Archived at WebCite]
- Bionor Immuno AS. An open Phase I/IIa study to evaluate the safety and effect of therapeutic HIV-1 immunization using Vacc-4x + rhuGM-CSF, and HIV-1 reactivation using romidepsin, on the viral reservoir in virologically suppressed HIV-1 infected adults on cART. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on March 3, 2014. NLM Identifier: NCT02092116. Available at: https://www.clinicaltrials.gov/ct2/show/NCT02092116. Last accessed on April 10, 2018.
- National Institute of Allergy and Infectious Diseases (NIAID). A Phase I/II study of single dose romidepsin in HIV-infected adults with suppressed viremia on antiretroviral therapy to assess safety, tolerability, and activation of HIV-1 expression. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on August 28, 2013. NLM Identifier: NCT01933594. Available at: https://www.clinicaltrials.gov/ct2/show/NCT01933594. Last accessed on April 10, 2018.
- IrsiCaixa. An open label Phase I trial to evaluate the safety and effect of HIVconsv vaccines in combination with histone deacetylase inhibitor romidepsin on the viral rebound kinetic after treatment interruption in early treated HIV-1 infected individuals (BCN02-Romi). In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on November 9, 2015. NLM Identifier: NCT02616874. Available at: https://www.clinicaltrials.gov/ct2/show/NCT02616874. Last accessed on April 10, 2018.
- Rockefeller University. A Phase 2a, randomized study of romidepsin with or without 3BNC117 to evaluate the effects on the HIV-1 reservoir (ROADMAP). In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on July 26, 2016. NLM Identifier: NCT02850016. Available at: https://clinicaltrials.gov/ct2/show/NCT02850016. Last accessed on April 10, 2018.
- National Institute of Allergy and Infectious Diseases (NIAID): News release, dated June 16, 2009. NIAID invites applications to conduct basic research on HIV persistence: studies key to search for a cure. Available at: https://wayback.archive-it.org/7761/20160907080510/http://www.niaid.nih.gov/news/newsreleases/Archive/2009/Pages/HIV_persistence.aspx. Last accessed on April 10, 2018.
- Siliciano RF, Greene WC. HIV latency. Cold Spring Harb Perspect Med. 2011 Sep;1(1):a007096. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234450/. Last accessed on April 10, 2018.
- Rasmussen TA, Tolstrup M, Winckelmann A, Ostergaard L, Søgaard OS. Eliminating the latent HIV reservoir by reactivation strategies. Hum Vaccin Immunother. 2013 Apr 1;9(4):790-799. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903897/. Last accessed on April 10, 2018.
- National Institutes of Health (NIH). NIH Clinical Research Trials and You. Available at: http://www.nih.gov/health-information/nih-clinical-research-trials-you. Last accessed on April 10, 2018.
- Søgaard OS, Graversen ME, Leth S, et al. The depsipeptide romidepsin reverses HIV-1 latency in vivo. PLoS Pathog. 2015 Sep; 11(9): e1005142. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4575032/. Last accessed on April 10, 2018.
- Aarhus University Hospital. Early administration of latency reversing therapy and broadly neutralizing antibodies to limit the establishment of the HIV-1 reservoir during initiation of antiretroviral treatment - a randomized controlled trial. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on January 20, 2017. NLM Identifier: NCT03041012. Available at: https://clinicaltrials.gov/ct2/show/NCT03041012. Last accessed on April 10, 2018.
- IrsiCaixa. Safety and immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv candidate HIV-1 vaccines in recently HIV-1 infected individuals with early viral suppression after initiation of antiretroviral therapy (HAART). In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on October 4, 2012. NLM Identifier: NCT01712425. Available at: https://clinicaltrials.gov/ct2/show/NCT01712425. Last accessed on April 10, 2018.
- Leth S, Schleimann MH, Nissen SK, et al. Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial. Lancet HIV. 2016 Oct;3(10):e463-72. Available at: http://www.natap.org/2016/HIV/PIIS23523018163005581.pdf. Last accessed on April 10, 2018.
- McMahon D, Zheng L, Cyktor JC, et al. Single romidepsin infusions do not increase HIV expression in persons on ART (A5315). Abstract presented at: Conference on Retroviruses and Opportunistic Infections (CROI); March 4–7, 2018; Boston, MA. Abstract 72. Available at: http://www.croiconference.org/sessions/single-romidepsin-infusions-do-not-increase-hiv-expression-persons-art-a5315. Last accessed on April 10, 2018. [Archived at WebCite]
Last Reviewed: April 9, 2018